Drug Profile

Prosetin - ProJenX

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Columbia University; Project A.L.S.
Developer ProJenX
Class Neuroprotectants; Small molecules
Mechanism of Action Mitogen-activated protein kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Amyotrophic lateral sclerosis
New Molecular Entity Yes

Highest Development Phases

No development reported Amyotrophic lateral sclerosis

Most Recent Events

28 Mar 2025 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis in USA (PO)
28 Mar 2024 US FDA removed a partial clinical hold on phase I study PRO-101 for Amyotrophic lateral sclerosis
14 Feb 2024 ProJenX receives European authorization for clinical trial of prosetin in Amyotrophic lateral sclerosis (ALS)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com